Anavex Life Sciences Corp (AVXL):企業の財務・戦略的SWOT分析

◆英語タイトル:Anavex Life Sciences Corp (AVXL) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH57663FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年2月
◆ページ数:46
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Anavex Life Sciences Corp (AVXL) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Anavex Life Sciences Corp (Anavex) is a clinical-stage biopharmaceutical company that focuses on developing differentiated therapeutics for the treatment of neurodegenerative and other central nervous systems (CNS) diseases, pain and various types of cancer. The company’s target indications include Alzheimer’s disease, Parkinson’s disease, Rett syndrome, epilepsy, neuropathic pain, depression, prostate cancer, pancreatic cancer infantile spasms, fragile X syndrome, Angelman syndrome, multiple sclerosis, depression, stroke, frontotemporal dementia, visceral pain, acute and neuropathic Pain and malignant melanoma. Its pipeline comprises one drug candidate and several compounds in diverse stages of pre-clinical study. Anavex’s lead compound ANAVEX 2-73 is being developed for the treatment of Alzheimer’s disease, Parkinson’s disease and potentially other CNS diseases, including rare diseases. Anavex is headquartered in New York, the US.

Anavex Life Sciences Corp Key Recent Developments

Feb 22,2021: Anavex Life Sciences announces participation at upcoming Worldwide National Institutes of Health (NIH) panel at Rare Disease Day
Feb 19,2021: Anavex Life Sciences announces participation at Precision in Clinical Trials Virtual Summit
Feb 11,2021: Anavex Life Sciences Reports Fiscal 2021 First Quarter Financial Results And Business Outlook
Feb 08,2021: Anavex Life Sciences to Announce Fiscal 2021 First Quarter Financial Results and Business Outlook on Thursday, February 11, 2021
Dec 28,2020: Anavex Life Sciences reports fiscal 2020 year end financial results and clinical program updates

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Anavex Life Sciences Corp – Key Facts
Anavex Life Sciences Corp – Key Employees
Anavex Life Sciences Corp – Key Employee Biographies
Anavex Life Sciences Corp – Major Products and Services
Anavex Life Sciences Corp – History
Anavex Life Sciences Corp – Company Statement
Anavex Life Sciences Corp – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Anavex Life Sciences Corp – Business Description
R&D Overview
Anavex Life Sciences Corp – Corporate Strategy
Anavex Life Sciences Corp – SWOT Analysis
SWOT Analysis – Overview
Anavex Life Sciences Corp – Strengths
Anavex Life Sciences Corp – Weaknesses
Anavex Life Sciences Corp – Opportunities
Anavex Life Sciences Corp – Threats
Anavex Life Sciences Corp – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Anavex Life Sciences Corp, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 22, 2021: Anavex Life Sciences announces participation at upcoming Worldwide National Institutes of Health (NIH) panel at Rare Disease Day
Feb 19, 2021: Anavex Life Sciences announces participation at Precision in Clinical Trials Virtual Summit
Feb 11, 2021: Anavex Life Sciences Reports Fiscal 2021 First Quarter Financial Results And Business Outlook
Feb 08, 2021: Anavex Life Sciences to Announce Fiscal 2021 First Quarter Financial Results and Business Outlook on Thursday, February 11, 2021
Dec 28, 2020: Anavex Life Sciences reports fiscal 2020 year end financial results and clinical program updates
Aug 06, 2020: Anavex Life Sciences reports fiscal 2020 third quarter financial results and provides business updates
May 07, 2020: Anavex Life Sciences reports fiscal 2020 second quarter financial results and provides business updates
Mar 31, 2020: Anavex Life Sciences provides update on clinical program development as response to covid-19
Feb 06, 2020: Anavex Life Sciences reports fiscal 2020 first quarter financial results and provides clinical study updates
Feb 04, 2020: Anavex Life Sciences to present and participate in a panel at the 2020 BIO CEO & Investor Conference
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Anavex Life Sciences Corp, Key Facts
Anavex Life Sciences Corp, Key Employees
Anavex Life Sciences Corp, Key Employee Biographies
Anavex Life Sciences Corp, Major Products and Services
Anavex Life Sciences Corp, History
Anavex Life Sciences Corp, Subsidiaries
Anavex Life Sciences Corp, Key Competitors
Anavex Life Sciences Corp, Ratios based on current share price
Anavex Life Sciences Corp, Annual Ratios
Anavex Life Sciences Corp, Interim Ratios
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Anavex Life Sciences Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Anavex Life Sciences Corp (AVXL):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • ImmuCell Corp (ICCC):企業の財務・戦略的SWOT分析
    ImmuCell Corp (ICCC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Caltex Australia Ltd (CTX):企業の財務・戦略的SWOT分析
    Caltex Australia Ltd (CTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • KPMG International:企業の戦略・SWOT・財務情報
    KPMG International - Strategy, SWOT and Corporate Finance Report Summary KPMG International - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Cardinal Health Inc (CAH):医療機器:M&Aディール及び事業提携情報
    Summary Cardinal Health Inc (Cardinal Health) is a company that provides integrated healthcare services and products. It distributes branded and generic drugs; and specialty medicines; over-the-counter healthcare and consumer products; medical equipment; surgical devices; and laboratory products. It …
  • Zimnat Group:企業の戦略・SWOT・財務情報
    Zimnat Group - Strategy, SWOT and Corporate Finance Report Summary Zimnat Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Unique Catering & Management Services Ltd:企業の戦略・SWOT・財務情報
    Unique Catering & Management Services Ltd - Strategy, SWOT and Corporate Finance Report Summary Unique Catering & Management Services Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Kazakhtelecom (KZTK):企業の財務・戦略的SWOT分析
    Kazakhtelecom (KZTK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Polydex Pharmaceuticals Ltd (POLXF):企業の財務・戦略的SWOT分析
    Summary Polydex Pharmaceuticals Ltd (PPL) is a manufacturer and marketer of pharmaceutical intermediates for human and veterinary pharmaceutical markets. The company manufactures and sells bulk quantities of dextran and derivative products. Its dextran and its derivatives can be used as adjuvants, e …
  • Cyclacel Pharmaceuticals Inc (CYCC):製薬・医療:M&Aディール及び事業提携情報
    Summary Cyclacel Pharmaceuticals Inc (Cyclacel) is a biopharmaceutical company that develops oral therapies. The company develops small molecule drugs that target various phases of cell cycle control for the treatment of cancer and other serious diseases. Its products include sapacitabine, selicicli …
  • Trivitron Healthcare Pvt Ltd:企業のM&A・事業提携・投資動向
    Trivitron Healthcare Pvt Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Trivitron Healthcare Pvt Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • Genera Biosystems Ltd (GBI)-製薬・医療分野:企業M&A・提携分析
    Summary Genera Biosystems Ltd (GBL) is a developer and commercializer of multiplexed molecular diagnostic testing products. The company offers RTIplex and PapType molecular diagnostic test. Its RTIplex is a multiplexed and automated PCR based test for detection of viral and bacterial respiratory pat …
  • ProMetic Life Sciences Inc (PLI):企業の財務・戦略的SWOT分析
    ProMetic Life Sciences Inc (PLI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Genmedica Therapeutics SL:製薬・医療:M&Aディール及び事業提携情報
    Summary Genmedica Therapeutics SL (Genmedica) is a clinical-stage biopharmaceutical company that researches, discovers and develops orally available NCEs for the treatment of diabetes. The company’s expertise spans provides development of specific, dual-action, small molecule inhibitors that targets …
  • Tetherex Pharmaceuticals Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Tetherex Pharmaceuticals Corp (Tetherex Pharmaceuticals) is a clinical-stage biopharmaceutical company which develops novel medicines for the treatment of inflammation, thrombosis and tumor metastasis. Its lead pipeline product candidate SelK2, a humanized monoclonal antibody targets a cell …
  • Seven-Eleven Japan Co., Ltd.:企業の戦略・SWOT・財務情報
    Seven-Eleven Japan Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Seven-Eleven Japan Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Temple Hotels Inc.:企業の戦略・SWOT・財務分析
    Temple Hotels Inc. - Strategy, SWOT and Corporate Finance Report Summary Temple Hotels Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Berger Paints India Ltd (BERGEPAINT):企業の財務・戦略的SWOT分析
    Berger Paints India Ltd (BERGEPAINT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Cabela’S Inc:企業の戦略・SWOT・財務分析
    Cabela'S Inc - Strategy, SWOT and Corporate Finance Report Summary Cabela'S Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Dignity Health-製薬・医療分野:企業M&A・提携分析
    Summary Dignity Health is a healthcare service provider that offers patient care services. The center provides health care services that include allergy, behavioral health, anesthesiology, cardiology, chronic care, geriatrics, dermatology, emergency medicine, endocrinology, gastroenterology, immunol …
  • ethris GmbH-製薬・医療分野:企業M&A・提携分析
    Summary ethris GmbH (Ethris) is a biotechnology company that develops and manufactures therapeutics. The company develops therapeutics based on its proprietary platform technologies. It uses technologies including magnetovax and SNIM RNA. Ethris’ magnetovax is a platform for personalized tumor vacci …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆